Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens

Enzalutamide is a nonsteroidal antiandrogen for the treatment of metastatic castration-resistant prostate cancer (mCRPC) both before and after chemotherapy. Enzalutamide is more effective than its predecessor bicalutamide, which was analyzed in head-to-head studies of patients with CRPC. This family...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Yusuke, Sadar, Marianne D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818862/
https://www.ncbi.nlm.nih.gov/pubmed/29497605
http://dx.doi.org/10.2147/RRU.S157116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818862/
https://www.ncbi.nlm.nih.gov/pubmed/29497605
http://dx.doi.org/10.2147/RRU.S157116

Ejemplares similares